| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Research |
Y Liu, Internal Medicine, Charles R. Drew University of Medicine & Science, Los Angeles, 90059, United States
Y Nakagawa, Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan
Y Wang, Internal Medicine, Charles R. Drew University of Medicine & Science, Los Angeles, United States
L Liu, Department of Endocrinology & Metabolism, Shanghai Jiaotong University Affiliated Sixth People Hospital, Shanghai Diabetes Institute, Shanghai, China
H Du, Department of Pediatrics, First Hospital, JiLin University,, Changchun, China
W Wang, Internal Medicine, Charles R. Drew University of Medicine & Science,, Los Angeles, United States
X Ren, Internal Medicine, Charles R. Drew University of Medicine & Science, Los Angeles, United States
K Lutfy, Department of Pharmaceutical Sciences, College of Pharmacy, Western University of Health Sciences, Pomona, United States
T Friedman, Division of Endocrinology, The Charles R. Drew University of Medicine & Sciences-UCLA School of Medicine, Los Angeles, United States
Correspondence: Yanjun Liu, Email: dryanjunliu{at}hotmail.com
Abstract
Intracellular glucocorticoid receptor (GR) function determines tissue sensitivity to glucocorticoids (GCs) and strongly affects the development of type 2 diabetes and obesity. 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) mediates intracellular steroid exposure to mouse liver GR by prereceptor reactivation of GCs and is crucially dependent on hexose-6-phosphate dehydrogenase (H6PDH)-generating NADPH system. Pharmacological inhibition of 11β-HSD1 improves insulin intolerance and obesity. Here, we evaluated the potential beneficial effects of 11β-HSD1 inhibitor carbenoxolone (CBX) in diet-induced obese and insulin resistant (DIO) mice by examining the possible influence of CBX on the expression of GR, 11β-HSD1, and H6PDH in vivo and in vitro in hepatocytes. Treatment of DIO mice with CBX markedly reduced hepatic GR mRNA levels and reduced weight gain, hyperglycemia, and insulin resistance. The reduction of hepatic GR gene expression was accompanied by CBX-induced inhibition of both 11β-HSD1 and H6PDH activity and mRNA in the liver. Moreover, CBX treatment also suppressed the expression of both phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase enzyme (G6Pase) mRNA and improved hepatic [1, 2-3H] deoxy-D-glucose uptake in DIO mice. In addition, treatment of primary cultures of hepatocytes with increasing concentrations of CBX led to a dose-dependent down-regulation of GR mRNA levels which correlated with the suppression of both 11β-HSD1 and H6PDH activity and their gene expression. Addition of CBX to primary hepatocytes also resulted in suppression of both PEPCK and G6Pase mRNA levels. These findings suggest that CBX exerts some of its beneficial effects, at least in part, by inhibiting hepatic GR and H6PDH expression.
This article has been cited by other articles:
|
|
 |
|
  J. F. Ndisang and A. Jadhav Up-Regulating the Hemeoxygenase System Enhances Insulin Sensitivity and Improves Glucose Metabolism in Insulin-Resistant Diabetes in Goto-Kakizaki Rats Endocrinology, June 1, 2009; 150(6): 2627 - 2636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Ndisang, N. Lane, and A. Jadhav Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1029 - E1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Ndisang and A. Jadhav Heme oxygenase system enhances insulin sensitivity and glucose metabolism in streptozotocin-induced diabetes Am J Physiol Endocrinol Metab, April 1, 2009; 296(4): E829 - E841. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
